Compare PSTG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSTG | RPRX |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 19.5B |
| IPO Year | 2015 | 2020 |
| Metric | PSTG | RPRX |
|---|---|---|
| Price | $67.30 | $49.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $90.05 | $50.00 |
| AVG Volume (30 Days) | 2.1M | ★ 2.6M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.88% |
| EPS Growth | ★ 77.42 | N/A |
| EPS | 0.55 | ★ 1.78 |
| Revenue | ★ $3,662,843,000.00 | $2,378,193,000.00 |
| Revenue This Year | $21.76 | $38.30 |
| Revenue Next Year | $15.70 | $4.80 |
| P/E Ratio | $123.45 | ★ $28.08 |
| Revenue Growth | ★ 15.61 | 5.06 |
| 52 Week Low | $43.51 | $31.58 |
| 52 Week High | $100.59 | $49.99 |
| Indicator | PSTG | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 67.49 |
| Support Level | $64.57 | $35.32 |
| Resistance Level | $76.63 | N/A |
| Average True Range (ATR) | 2.80 | 0.92 |
| MACD | 0.86 | 0.14 |
| Stochastic Oscillator | 100.00 | 94.35 |
Pure Storage Inc is a U.S.-based company that provides an enterprise data storage platform that transforms business through a dramatic increase in performance and reduction in complexity and costs. It generates revenue from two sources: product revenue, which includes the sale of integrated storage hardware and embedded operating system software; and subscription services revenue, which includes Evergreen Storage subscriptions, a unified subscription that includes Pure as-a-Service, Cloud Block Store, and Portworx. Subscription services revenue also includes professional services offerings such as installation and implementation consulting services.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.